


PHARMACEUTICAL 2020

RespireRx Pharmaceuticals Inc. Rank 283 of 362







PHARMACEUTICAL 2020

## RespireRx Pharmaceuticals Inc. Rank 283 of 362

The relative strengths and weaknesses of RespireRx Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RespireRx Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 1,761% points. The greatest weakness of RespireRx Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 162% points.

The company's Economic Capital Ratio, given in the ranking table, is -445%, being 142% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	45
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,490
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	405
Other Liabilities	0
Other Net Income	26
Property and Equipment	0
Research and Development	599
Revenues	0
Selling, General and Administrative Expense	1,137

Output Variable	Value in 1000 USD
Assets	45
Liabilities	7,490
Expenses	2,141
Stockholders Equity	-7,445
Net Income	-2,115
Comprehensive Net Income	-2,115
Economic Capital Ratio	-445%

